Invesaro

Stocks COGT Earnings

Earnings

Cogent Biosciences, Inc. (COGT) earnings

Quarterly results of Cogent Biosciences, Inc. as filed with the SEC: revenue, net income and earnings per share for each of the last 8 quarters, the latest results release and when the next one is expected.

Free, no password. An email when COGT files with the SEC.

Next earnings date

Cogent Biosciences, Inc. is expected to report around February 16, 2027. That is an estimate from its filing rhythm (a year after the same report last year), not a date the company has announced.

Latest quarter: Q3 FY2026

In Q3 FY2026 (ended September 30, 2026) Cogent Biosciences, Inc. reported revenue of - and a net loss of $111.4M.

Diluted earnings per share were -$0.59.

Filed with the SEC on November 5, 2026.

Net income by quarter
Q4 24: -$67.9M -$67.9M Q4 24Q1 25: -$72M -$72M Q1 25Q2 25: -$73.5M -$73.5M Q2 25Q3 25: -$80.9M -$80.9M Q3 25Q4 25: -$102.5M -$102.5M Q4 25Q1 26: -$97.4M -$97.4M Q1 26Q2 26: -$96.4M -$96.4M Q2 26Q3 26: -$111.4M -$111.4M Q3 26

Quarter by quarter

QuarterEndedRevenuevs year agoNet incomeEPS
Q3 FY2026September 30, 2026---$111.4M-$0.59
Q2 FY2026June 30, 2026---$96.4M-$0.52
Q1 FY2026March 31, 2026---$97.4M-$0.53
Q4 FY2025December 31, 2025---$102.5M-
Q3 FY2025September 30, 2025---$80.9M-$0.50
Q2 FY2025June 30, 2025---$73.5M-$0.53
Q1 FY2025March 31, 2025---$72M-$0.52
Q4 FY2024December 31, 2024---$67.9M-

Fourth quarters are the fiscal year minus the first three, as most companies report no separate Q4 figures.

Results filings

When is Cogent Biosciences, Inc.'s next earnings date?

Cogent Biosciences, Inc. is expected to report around February 16, 2027. That is an estimate from its filing rhythm (a year after the same report last year), not a date the company has announced.

Get an email when COGT reports

Follow COGT and we email you its next results the day they are filed, with the numbers explained.

Free, no password. An email when COGT files with the SEC.

Source: quarterly figures Cogent Biosciences, Inc. tags in its 10-Q and 10-K filings (SEC EDGAR XBRL). Not investment advice.

Everything about Cogent Biosciences, Inc.